Company: TBPH
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001558370-25-011408
Chunk: 2

Company: Theravance Biopharma, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1F
Chunk 2
---
ITEM 1.    FINANCIAL STATEMENTS

​

THERAVANCE BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except per share data)

​​​​​​​​​June 30, ​December 31, ​    2025    2024Assets​​​​​​Current assets:​​​​​​Cash and cash equivalents ​$ 281,927​$ 37,797Short-term marketable securities​  56,877​  50,553Receivables from collaborative arrangements ​  21,919​  18,440Receivables from milestones and royalty assets​​ —​​ 50,000Other prepaid and current assets  ​​ 5,571​​ 4,277Total current assets ​  366,294​  161,067Property and equipment, net ​  6,641​  7,418Operating lease assets​​ 26,493​​ 28,354Future contingent milestone and royalty assets​​ —​​ 144,200Restricted cash ​  836​  836Other assets​​ 25,771​​ 12,286Total assets ​$ 426,035​$ 354,161​​​​​​​Liabilities and Shareholders' Equity​​​​​​Current liabilities:​​​​​​Accounts payable ​$ 1,675​$ 2,242Accrued personnel-related expenses ​  7,259​  7,019Accrued clinical and development expenses ​  3,783​  1,058Accrued general and administrative expenses​​ 2,459​​ 2,987Operating lease liabilities​​ 10,896​​ 10,712Income tax payable​​ 26,696​​ 5,853Other accrued liabilities​  1,865​  2,214Total current liabilities ​  54,633​  32,085Long-term operating lease liabilities​​ 35,561​​ 39,108Future royalty payment contingency​​ 31,640​​ 30,334Unrecognized tax benefits​​ 77,805​​ 75,199Other long-term liabilities​​ 1,548​​ 1,890Commitments and contingencies (Note 11)​​​​​​​​​​​​​Shareholders’ Equity​​​​​​Preferred shares, $0.00001 par value per share: 230 shares authorized, no shares issued or outstanding​